972 filings
Page 6 of 49
8-K
1zbkrxbgka ah9cb
28 Jul 22
Acer Therapeutics and Relief Therapeutics Announce FDA Acceptance for Review of NDA Resubmission for ACER-001 for Treatment of UCDs
9:00am
8-K
wjbao7fg
18 Jul 22
Acer Therapeutics Announces Resubmission of New Drug Application for ACER-001 for Treatment of UCDs
8:45am
8-K
mlus d006a9l6b735p7
29 Jun 22
Regulation FD Disclosure
9:03am
8-K
unex372 1wy332r9xlc
27 Jun 22
Other Events
9:00am
4
zx7cx4bmwinndw9hm xm
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:06pm
3
j74z2avvpk1737sitwi0
22 Jun 22
Acer Therapeutics / Tanya Hayden ownership change
4:04pm
8-K
piydognpvi0wzjvc
21 Jun 22
Acer Therapeutics Announces Promotion of Tanya Hayden to Chief Operating Officer
8:37am
8-K
84wzy46bov6 7oqi
7 Jun 22
Acer Therapeutics Issues Statement Regarding PDUFA Target Action Date for ACER-001
9:00am
8-K
anet7cu 7roc
31 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:04pm
8-K
usz0kmmd n4
23 May 22
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
0ynuzd3d dmhy
17 May 22
Other Events
4:21pm
424B2
nunzx
17 May 22
Prospectus for primary offering
4:12pm
8-K
o3qt0ekt
16 May 22
Acer Therapeutics Reports Q1 2022 Financial Results and Provides Corporate Update
12:00am
8-K
cc2qpg9 hqhbpq83d9ea
9 May 22
Phase 3 DiSCOVER clinical trial initiation expected by end of Q2 2022
9:01am
8-K
2x1h0d6ovv3m4rj7pd8
6 May 22
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
9:00am
424B3
nasp68
3 May 22
Prospectus supplement
4:01pm
EFFECT
dcv9dfeolz38iue6j594
3 May 22
Notice of effectiveness
12:15am
CORRESP
23toxxu2w9k9gg2mn8
28 Apr 22
Correspondence with SEC
12:00am